ALK+ NSCLC
Oncology · 2013–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| alectinib Adjuvant therapy of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following tumour resection in patients with tumours ≥4 cm or… | Mar 2026 | Recommended with restriction | no section in document |
| alectinib Adjuvant treatment in adult patients following tumour resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥4 cm… | May 2025 | Recommended with restriction | 9 individuals Medical Oncology Group · Rare Cancers Australia · Lung Foundation Australia · ALK Positive Australia |
| brigatinib Locally advanced (Stage IIIB) or metastatic (Stage IV) anaplastic lymphoma kinase (ALK)-positive non-squamous or not otherwise specified non-small cell lung… | Nov 2019 | Recommended with restriction | 70 individuals Lung Foundation Australia · Rare Cancers Australia |
| lorlatinib Treatment of patients with metastatic (Stage IV) ALK-positive non-small cell lung cancer (NSCLC) who have disease progression following treatment with a prior… | Nov 2019 | Recommended with restriction | 118 individuals Lung Foundation Australia · Rare Cancers Australia · Medical Oncology Group |
| alectinib Treatment of patients with ALK-positive locally advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) who have disease progression… | Jul 2017 | Recommended with restriction | 173 individuals Lung Foundation · Rare Cancers Australia · Medical Oncology Group |
| ceritinib Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have… | Nov 2016 | Recommended | 18 individuals Rare Cancers Australia · Lung Foundation · Medical Oncology Group |
| crizotinib Treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) following disease… | Nov 2014 | Recommended with restriction | 261 individuals |
| crizotinib Second-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who have experienced disease… | Nov 2013 | Noted | no section in document |
Who spoke
Rare Cancers Australia · Medical Oncology Group · Lung Foundation Australia · Lung Foundation · ALK Positive Australia
What the PBS pays
$56M in government benefit over 2024–25, across 8,547 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| alectinib | $31.8M |
| lorlatinib | $19.6M |
| brigatinib | $2.5M |
| crizotinib | $2.3M |
| ceritinib | $0.1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 9 technologies for this condition, recommending 8 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| alectinibAlectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer | TA1014 | recommended restricted | 2024-11 |
| brigatinibBrigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor | TA670 | recommended restricted | 2021-01 |
| lorlatinibLorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer | TA628 | recommended | 2020-05 |
| brigatinibBrigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib | TA571 | recommended restricted | 2019-03 |
| alectinibAlectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | recommended restricted | 2018-08 |
| ceritinibCeritinib for untreated ALK-positive non-small-cell lung cancer | TA500 | recommended restricted | 2018-01 |
| alectinibAlectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | TA438 | terminated | 2017-03 |
| crizotinibCrizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA422 | recommended restricted | 2016-12 |
| ceritinibCeritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer | TA395 | recommended restricted | 2016-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.